HPV Vaccine Trials: Lesions Aren’t Cancer — What Was Actually Proven?

Donate: 🙏Počastite nas kavicom https://www.buymeacoffee.com/slobodnipoI In this clip from Slobodni Podcast, attorney and author Mary Holland discusses controversial claims about early HPV vaccine clinical trials — including a Danish trial recruitment story, what the control groups reportedly received, and why cervical lesions (CIN) are not the same thing as proving cancer prevention as a final clinical outcome. What’s covered in this segment Surrogate endpoints vs. real outcomes: why preventing CIN lesions is not identical to proving fewer cancer cases Trial design questions: what “control” groups received and why that matters for interpreting safety results Time horizon problem: cancers often develop over decades, while trials had limited follow-up Safety signals & reporting language: how adverse events can be interpreted, categorized, or renamed in trial datasets Why this matters in Europe: EMA documentation relies heavily on manufacturer-submitted trial data — and critics argue the assumptions behind that data deserve scrutiny This is a discussion about evidence standards: what was measured, what was assumed, and what conclusions are justified. ▶️ Full episode link: https://www.youtube.com/playlist?list=PLJTy3oXCzHShsVuJ-zfiGnx96nuR-BNWB WEB: https://slobodnipodcast.hr/2026/02/08/obvezno-hpv-cjepivo-u-hrvatskoj-pitanja-koja-sluzbena-medicina-izbjegava/ Disclaimer: This clip presents the guest’s claims and interpretation. Viewers should consult primary trial publications, regulatory reviews, and independent safety assessments. #HPV #Gardasil #ClinicalTrials #MedicalEvidence #VaccinePolicy